338 related articles for article (PubMed ID: 20130140)
1. Three-dimensional organization of promyelocytic leukemia nuclear bodies.
Lang M; Jegou T; Chung I; Richter K; Münch S; Udvarhelyi A; Cremer C; Hemmerich P; Engelhardt J; Hell SW; Rippe K
J Cell Sci; 2010 Feb; 123(Pt 3):392-400. PubMed ID: 20130140
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of component exchange at PML nuclear bodies.
Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
4. PML nuclear body-residing proteins sequentially associate with HPV genome after infectious nuclear delivery.
Guion L; Bienkowska-Haba M; DiGiuseppe S; Florin L; Sapp M
PLoS Pathog; 2019 Feb; 15(2):e1007590. PubMed ID: 30802273
[TBL] [Abstract][Full Text] [Related]
5. Small Ubiquitin-like Modifier Alters IFN Response.
Maarifi G; Maroui MA; Dutrieux J; Dianoux L; Nisole S; Chelbi-Alix MK
J Immunol; 2015 Sep; 195(5):2312-24. PubMed ID: 26223657
[TBL] [Abstract][Full Text] [Related]
6. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
[TBL] [Abstract][Full Text] [Related]
7. Herpes virus induced proteasome-dependent degradation of the nuclear bodies-associated PML and Sp100 proteins.
Chelbi-Alix MK; de Thé H
Oncogene; 1999 Jan; 18(4):935-41. PubMed ID: 10023669
[TBL] [Abstract][Full Text] [Related]
8. Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1.
Sternsdorf T; Jensen K; Will H
J Cell Biol; 1997 Dec; 139(7):1621-34. PubMed ID: 9412458
[TBL] [Abstract][Full Text] [Related]
9. An Adenovirus DNA Replication Factor, but Not Incoming Genome Complexes, Targets PML Nuclear Bodies.
Komatsu T; Nagata K; Wodrich H
J Virol; 2016 Feb; 90(3):1657-67. PubMed ID: 26608315
[TBL] [Abstract][Full Text] [Related]
10. De novo assembly of a PML nuclear subcompartment occurs through multiple pathways and induces telomere elongation.
Chung I; Leonhardt H; Rippe K
J Cell Sci; 2011 Nov; 124(Pt 21):3603-18. PubMed ID: 22045732
[TBL] [Abstract][Full Text] [Related]
11. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies.
Engelhardt OG; Ullrich E; Kochs G; Haller O
Exp Cell Res; 2001 Dec; 271(2):286-95. PubMed ID: 11716541
[TBL] [Abstract][Full Text] [Related]
12. Death-domain associated protein-6 (DAXX) mediated apoptosis in hantavirus infection is counter-balanced by activation of interferon-stimulated nuclear transcription factors.
Khaiboullina SF; Morzunov SP; Boichuk SV; Palotás A; St Jeor S; Lombardi VC; Rizvanov AA
Virology; 2013 Sep; 443(2):338-48. PubMed ID: 23830076
[TBL] [Abstract][Full Text] [Related]
13. The number of PML nuclear bodies increases in early S phase by a fission mechanism.
Dellaire G; Ching RW; Dehghani H; Ren Y; Bazett-Jones DP
J Cell Sci; 2006 Mar; 119(Pt 6):1026-33. PubMed ID: 16492708
[TBL] [Abstract][Full Text] [Related]
14. REGgamma/PA28gamma proteasome activator interacts with PML and Chk2 and affects PML nuclear bodies number.
Zannini L; Buscemi G; Fontanella E; Lisanti S; Delia D
Cell Cycle; 2009 Aug; 8(15):2399-407. PubMed ID: 19556897
[TBL] [Abstract][Full Text] [Related]
15. Mobile foci of Sp100 do not contain PML: PML bodies are immobile but PML and Sp100 proteins are not.
Wiesmeijer K; Molenaar C; Bekeer IM; Tanke HJ; Dirks RW
J Struct Biol; 2002; 140(1-3):180-8. PubMed ID: 12490166
[TBL] [Abstract][Full Text] [Related]
16. Role of SUMO-1-modified PML in nuclear body formation.
Zhong S; Müller S; Ronchetti S; Freemont PS; Dejean A; Pandolfi PP
Blood; 2000 May; 95(9):2748-52. PubMed ID: 10779416
[TBL] [Abstract][Full Text] [Related]
17. Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1.
Dellaire G; Eskiw CH; Dehghani H; Ching RW; Bazett-Jones DP
J Cell Sci; 2006 Mar; 119(Pt 6):1034-42. PubMed ID: 16492707
[TBL] [Abstract][Full Text] [Related]
18. Contribution of the C-terminal regions of promyelocytic leukemia protein (PML) isoforms II and V to PML nuclear body formation.
Geng Y; Monajembashi S; Shao A; Cui D; He W; Chen Z; Hemmerich P; Tang J
J Biol Chem; 2012 Aug; 287(36):30729-42. PubMed ID: 22773875
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
Bailey D; O'Hare P
Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
[TBL] [Abstract][Full Text] [Related]
20. SUMOylation promotes PML degradation during encephalomyocarditis virus infection.
El McHichi B; Regad T; Maroui MA; Rodriguez MS; Aminev A; Gerbaud S; Escriou N; Dianoux L; Chelbi-Alix MK
J Virol; 2010 Nov; 84(22):11634-45. PubMed ID: 20826694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
